D. Sang

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study

Wei Li, P. Yuan, Biyun Wang, 2021, Frontiers in Oncology.

High expression of prolyl 4-hydroxylase subunit alpha-2 in lung adenocarcinoma indicates poor prognosis

Yu-rong Zhang, D. Sang, Xiao-Hong Lu, 2022, Clinics.

Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer

Bing-he Xu, P. Yuan, F. Ma, 2018, Thoracic cancer.

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Wei Li, P. Yuan, Biyun Wang, 2020, Cancer medicine.

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population

Yang Luo, Bing-he Xu, P. Yuan, 2016, Medicine.

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up

J. Ju, Jiayu Wang, Xue Wang, 2024, Thoracic cancer.

Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study

Yizhao Xie, D. Sang, S. You, 2023, Therapeutic advances in medical oncology.